{"result": {"id": "19b92203-2371-4262-bd52-cdf941f509ea", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>HYPERTENSION<|>EVENT<|>Hypertension is a chronic medical condition characterized by elevated blood pressure, often comorbid with COPD and requiring careful medication management to avoid interactions.\")\n##\n(\"entity\"<|>SMOKING CESSATION<|>EVENT<|>A critical lifestyle intervention for both COPD and hypertension patients to reduce disease progression and complications.\")\n##\n(\"entity\"<|>BRONCHODILATORS<|>EVENT<|>Medications used to relax bronchial muscles in COPD patients, with potential cardiovascular considerations in comorbid hypertension.\")\n##\n(\"entity\"<|>IMMUNE SYSTEM DISEASES<|>EVENT<|>Conditions that may contribute to secondary hypertension through vascular or renal mechanisms, requiring integrated management.\")\n##\n(\"relationship\"<|>HYPERTENSION<|>COPD<|>Frequent comorbidity requiring coordinated treatment due to overlapping medication effects<|>8)\n##\n(\"relationship\"<|>HYPERTENSION<|>Β1 RECEPTOR BLOCKER<|>First-line antihypertensive agents that require selectivity in COPD patients<|>9)\n##\n(\"relationship\"<|>COPD<|>SMOKING CESSATION<|>Primary preventive measure to slow COPD progression<|>9)\n##\n(\"relationship\"<|>HYPERTENSION<|>SMOKING CESSATION<|>Key lifestyle modification for blood pressure control<|>8)\n##\n(\"relationship\"<|>COPD<|>BRONCHODILATORS<|>Core pharmacological therapy for symptom relief<|>9)\n##\n(\"relationship\"<|>IMMUNE SYSTEM DISEASES<|>HYPERTENSION<|>May induce secondary hypertension through inflammatory pathways<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558774, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 385, "prompt_tokens": 3001, "total_tokens": 3386, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2944}, "prompt_cache_hit_tokens": 2944, "prompt_cache_miss_tokens": 57}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 嗽、咳痰或活动后气  短等症状的高危人群 ,应推荐肺功能检查 。肺通气功  能测定是 COPD 的重要诊断方法 。 吸入支气管舒张  剂后的第 1 秒用力呼气容积(forced expiratory vol- umein firstsecond,FEV1) 和用力肺活量(forced vital capacity,FVC) 的比值(FEV1/FVC) <70%是 COPD  的诊断标准[642] 。\n　　　高血压和 COPD合并时 , 两者的治疗均无需调  整 。 由于 β受体阻滞剂和 β受体激动剂分别用于高血  压(或其他心血管疾病) 和 COPD 的治疗 ,引起临床医  生的顾虑 。研究显示 ,选择性 β1 受体阻滞剂对于吸入  长效 β2 受体激动剂的 COPD患者的肺功能获益并无  影响 , 也不增加吸入 β2  受体激动剂的心血管风险、 COPD急性加重或全因死亡风险 。相反 ,选择性 β1 受  体阻滞剂的使用能够减少 COPD急性加重和全因死  亡风险[643-645] 。 因此 ,无论患者是否在吸入 β2  受体激  动剂 ,高血压合并 COPD 时 ,推荐在病情需要的情况  下使用选择性 β1 受体阻滞剂 ,但不推荐使用非选择性  β受体阻滞剂。\nCOPD 的诊治遵循 COPD指南的建议规范化治\n\n\n\n疗和个体化长期管理[642] 。稳定期 COPD患者使用长 效 β受体激动剂和/或长效 M 受体阻断剂吸入制剂 , 心血管安全性总体上是安全的[646-647] 。对于有心功能 不全的稳定期 COPD患者 ,使用支气管扩张剂可能会 增加 心 功 能 不 全 加 重 的 风 险 , 使 用 时 需 要 谨 慎 观 察[647-648] 。使用 “长效 β受体激动剂 +长效 M 受体阻 断剂+吸入糖皮质激素”三联吸入制剂可降低 COPD患 者的全因死亡风险,而不增加心血管疾病死亡风险[649-650] 。\n　　　生活方式的改变对于高血压和 COPD等慢性疾 病都是非常重要的 ,包括戒烟与运动等 。对于吸烟患 者 ,推荐患者戒烟并提供戒烟指导[642] 。 同时需要减少 空气污染、燃料烟雾和职业粉尘等环境暴露因素[642] 。\n8.12   高血压与免疫系统疾病\n\n要点 8L   高血压与免疫系统疾病\n　　　·积极治疗原发疾病 ,综合干预并存的心血管危 险因素 ,尽量减少导致血压升高及血管损伤的原发疾 病治疗的药物用量。\n　　　·参照一般人群进行降压治疗 ,选择合适的降 压药。\n\n　　许多免疫系统疾病可合并高血压 ,部分疾病发病 机制不明 ,但常为多种机制并存 ,如肾血管性病变、肾 实质性病变、药物\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>COPD<|>EVENT<|>Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease characterized by airflow obstruction and symptoms like cough, shortness of breath, and sputum production. It is diagnosed using spirometry with a post-bronchodilator FEV1/FVC ratio <70%. COPD management includes bronchodilators, corticosteroids, and lifestyle changes like smoking cessation.\")\n##\n(\"entity\"<|>FEV1<|>EVENT<|>Forced Expiratory Volume in the first second (FEV1) is a measure of lung function used in the diagnosis and monitoring of COPD.\")\n##\n(\"entity\"<|>FVC<|>EVENT<|>Forced Vital Capacity (FVC) is the total amount of air exhaled during a forced breath, used alongside FEV1 to diagnose COPD.\")\n##\n(\"entity\"<|>Β1 RECEPTOR BLOCKER<|>EVENT<|>Selective β1 receptor blockers are medications used in hypertension and cardiovascular diseases, which can be safely used in COPD patients without affecting lung function or increasing cardiovascular risks.\")\n##\n(\"entity\"<|>Β2 RECEPTOR AGONIST<|>EVENT<|>Long-acting β2 receptor agonists are bronchodilators used in COPD treatment to relieve symptoms and improve lung function.\")\n##\n(\"entity\"<|>TRIPLE INHALER THERAPY<|>EVENT<|>Combination therapy of long-acting β2 agonists, long-acting muscarinic antagonists, and inhaled corticosteroids reduces all-cause mortality in COPD patients without increasing cardiovascular risks.\")\n##\n(\"relationship\"<|>COPD<|>FEV1<|>FEV1 is a key diagnostic measure for COPD<|>9)\n##\n(\"relationship\"<|>COPD<|>FVC<|>FVC is used alongside FEV1 to diagnose COPD<|>9)\n##\n(\"relationship\"<|>Β1 RECEPTOR BLOCKER<|>COPD<|>Selective β1 receptor blockers can be used in COPD patients without worsening lung function<|>7)\n##\n(\"relationship\"<|>Β2 RECEPTOR AGONIST<|>COPD<|>Long-acting β2 agonists are a primary treatment for COPD<|>8)\n##\n(\"relationship\"<|>TRIPLE INHALER THERAPY<|>COPD<|>Triple inhaler therapy reduces mortality in COPD patients<|>8)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_daa8cdf9911750978a28250a41d9ba2d3d8c3ecb15b3a944fbc37ab4e5585ec5_v2"}